1
|
Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production.
|
Immunity
|
2012
|
2.80
|
2
|
Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals.
|
Proc Natl Acad Sci U S A
|
2007
|
1.84
|
3
|
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
|
Clin Cancer Res
|
2007
|
1.84
|
4
|
The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner.
|
Immunology
|
2006
|
1.44
|
5
|
CD1d ligation on human monocytes directly signals rapid NF-kappaB activation and production of bioactive IL-12.
|
Proc Natl Acad Sci U S A
|
2005
|
1.40
|
6
|
Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells.
|
J Immunol
|
2004
|
1.27
|
7
|
Impaired cell surface expression of human CD1d by the formation of an HIV-1 Nef/CD1d complex.
|
Virology
|
2005
|
1.19
|
8
|
Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses.
|
J Virol
|
2007
|
1.13
|
9
|
Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function.
|
J Clin Invest
|
2010
|
1.06
|
10
|
CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion.
|
Proc Natl Acad Sci U S A
|
2003
|
1.06
|
11
|
Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells.
|
J Immunol
|
2013
|
1.05
|
12
|
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.
|
Clin Cancer Res
|
2008
|
1.01
|
13
|
Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
|
Cancer Res
|
2006
|
0.96
|
14
|
The A2aR adenosine receptor controls cytokine production in iNKT cells.
|
Eur J Immunol
|
2010
|
0.96
|
15
|
CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity.
|
Exp Dermatol
|
2005
|
0.96
|
16
|
Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.
|
PLoS One
|
2010
|
0.94
|
17
|
NKT-cell-based immunotherapies in clinical trials.
|
Clin Immunol
|
2011
|
0.93
|
18
|
Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells.
|
J Immunol
|
2008
|
0.92
|
19
|
CD1d-based combination therapy eradicates established tumors in mice.
|
J Immunol
|
2009
|
0.92
|
20
|
CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo.
|
J Virol
|
2006
|
0.91
|
21
|
Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo.
|
J Immunol
|
2009
|
0.90
|
22
|
Gestation stage-dependent mechanisms of invariant natural killer T cell-mediated pregnancy loss.
|
Proc Natl Acad Sci U S A
|
2006
|
0.90
|
23
|
Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro.
|
J Immunol
|
2013
|
0.89
|
24
|
Natural killer T cell-based cancer immunotherapy.
|
Clin Cancer Res
|
2006
|
0.88
|
25
|
CD1d activation and blockade: a new antitumor strategy.
|
J Immunol
|
2009
|
0.87
|
26
|
Loss of effector and anti-inflammatory natural killer T lymphocyte function in pathogenic simian immunodeficiency virus infection.
|
PLoS Pathog
|
2012
|
0.86
|
27
|
Phenotypic and functional characterization of long-term cultured rhesus macaque spleen-derived NKT cells.
|
J Immunol
|
2003
|
0.85
|
28
|
Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival.
|
Exp Hematol
|
2008
|
0.85
|
29
|
Heterogeneity in phenotype and function of CD8+ and CD4/CD8 double-negative Natural Killer T cell subsets in sooty mangabeys.
|
J Med Primatol
|
2010
|
0.84
|
30
|
Exploiting regulatory T-cell populations for the immunotherapy of cancer.
|
J Immunother
|
2007
|
0.84
|
31
|
Paucity of CD4+ natural killer T (NKT) lymphocytes in sooty mangabeys is associated with lack of NKT cell depletion after SIV infection.
|
PLoS One
|
2010
|
0.84
|
32
|
Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
|
Clin Immunol
|
2011
|
0.84
|
33
|
CD1 expression and CD1-restricted T cell activity in normal and tumour-bearing human liver.
|
Cancer Immunol Immunother
|
2006
|
0.83
|
34
|
Invariant natural killer T cells from rhesus macaque spleen and peripheral blood are phenotypically and functionally distinct populations.
|
J Med Primatol
|
2008
|
0.82
|
35
|
Protective role of regulatory decidual γδ T cells in pregnancy.
|
Clin Immunol
|
2011
|
0.82
|
36
|
Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis.
|
Hepatology
|
2012
|
0.80
|
37
|
Editorial: NKT get the 'flu: NKT cells as (mostly) good guys in influenza; monocytic cells as double agents.
|
J Leukoc Biol
|
2012
|
0.76
|
38
|
CD1d favors MHC neighborhood, GM1 ganglioside proximity and low detergent sensitive membrane regions on the surface of B lymphocytes.
|
Biochim Biophys Acta
|
2014
|
0.76
|
39
|
Comment on "Essential Role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung".
|
J Immunol
|
2010
|
0.75
|
40
|
Nuancing the proposed role of NKT cells in aging.
|
Virulence
|
2011
|
0.75
|
41
|
Analysis of the major histocompatibility complex in graft rejection revisited by gene expression profiles.
|
Transplantation
|
2004
|
0.75
|
42
|
Overview: NK-cell-based Immunotherapies: Toward & Into Clinical Trials.
|
Clin Immunol
|
2017
|
0.75
|